Open AccessPatient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial
Author(s) -
Ooki Akira,
Morita Satoshi,
Iwamoto Shigeyoshi,
Hara Hiroki,
Tanioka Hiroaki,
Satake Hironaga,
Kataoka Masato,
Kotaka Masahito,
Kagawa Yoshinori,
Nakamura Masato,
Shingai Tatsushi,
Ishikawa Masashi,
Miyake Yasuhiro,
Suto Takeshi,
Hashiguchi Yojiro,
Yabuno Taichi,
Sakamoto Junichi,
Tsuji Akihito,
Ando Masahiko,
Yamaguchi Kensei
Publication year - 2020
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.2826
Subject(s) - medicine , cetuximab , asymptomatic , colorectal cancer , chemotherapy , quality of life (healthcare) , adverse effect , oncology , chemotherapy regimen , cancer , gastroenterology , nursing
Background It remains unclear whether patients’ self‐perceptions of symptoms at baseline clinically impact the prognostic relevance, treatment efficacy, or toxicity profiles in metastatic colorectal cancer (mCRC) patients treated with the first‐line cetuximab and standard chemotherapy. Methods The data were collected from a prospective trial that assessed the relationships between quality of life (QOL), treatment efficacy, and adverse events (AEs). Results The analysis of 137 mCRC patients revealed a significant association between the presence of baseline tumor‐related symptoms and a lower overall survival (OS) compared to the absence of symptoms (HR, 2.49; 95% CI, 1.37‐4.62; P = .003). The asymptomatic responders had favorable outcomes compared to the symptomatic nonresponders (2‐year OS rates: 83.6% and 35.9%, respectively), while the symptomatic responders had similar outcomes to the asymptomatic nonresponders. The median postprogression survival differed significantly: 10.2 months for the symptomatic patients and 15.9 months for the asymptomatic patients (HR, 2.29; 95% CI, 1.25‐4.29, P = .008). The objective response rates and patient toxicity profiles were similar irrespective of the severity of baseline symptoms. Conclusion Baseline symptoms were associated with worse OS but not with impaired treatment efficacy or more frequent AEs in mCRC patients treated with cetuximab in addition to chemotherapy.